What CG Oncology’s Latest Earnings Tell You About the Business

CG Oncology (CGON) recently posted second quarter and first half 2026 results, giving investors fresh detail on how revenue and losses are tracking for this late stage bladder cancer focused biotech.

For the quarter ended June 30, 2026, CG Oncology reported revenue of US$1.16 million. The company recorded a net loss of US$79.06 million and a basic loss per share from continuing operations of US$0.90.

For the first six months of 2026, revenue totaled US$2.24 million. Over the same period, CG Oncology reported a net loss of US$139.26 million and a basic loss per share from continuing operations of US$1.61.

CG Oncology’s latest earnings update comes after a strong run in the stock, with the share price at US$76.99 and a year to date share price return of 84.23%, while the 1 year total shareholder return of 190.64% points to momentum that has continued to build in recent months.

If CG Oncology’s move has sharpened your focus on high growth healthcare opportunities, it can be useful to scan other companies in this space using our screener for 43 healthcare AI stocks

After a sharp move in CG Oncology’s stock and a wide gap between the current US$76.99 price and the range of value estimates, where does fair value really sit for this loss making biotech as you weigh the numbers next?

Preferred Price to Book Multiple of 6.6x: Is It Justified for CG Oncology?

Simply Wall St’s DCF model currently estimates a future cash flow value of $542.38 per share for CG Oncology, compared with the last close at $76.99. That implies a very large gap between the modelled fair value and where the stock is trading today.

The SWS DCF model projects CG Oncology’s future cash flows and then discounts those back to today’s value using an assumed required return. This approach focuses on the company’s potential to generate cash over time rather than near term earnings, which is useful for a business that remains loss making.

For a late stage biotech such as CG Oncology, where reported net income is currently negative and revenue is still relatively small at $6.23m, a cash flow based framework is often used by investors alongside other tools. Models of this kind tend to be sensitive to assumptions around future growth, margins and the timing of any shift from loss to profit. Therefore, the wide gap between the DCF output and the current $76.99 price is an input for further research rather than a standalone conclusion.

Result: DCF Fair value of $542.38 (UNDERVALUED)

However, CG Oncology still faces risks around ongoing losses of US$224.38m and the uncertainty that comes with multiple late stage clinical trials in progress.

Another View On CG Oncology’s Valuation

The P/B ratio offers a very different angle compared with the SWS DCF model. CG Oncology trades at 6.6x book value, which is below a peer average of 9x but well above the broader US biotechs group at 2.4x. That mix suggests both potential upside and valuation risk. Which signal do you put more weight on?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out CG Oncology for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With mixed signals around CG Oncology’s valuation and business progress, it can be helpful to move quickly and review the details yourself rather than rely on headlines. To see how the positives and concerns compare in one place, review the 2 key rewards and 1 important warning sign

Looking For More Investment Ideas Beyond CG Oncology?

If CG Oncology has sharpened your interest in opportunities, do not stop here. The real edge often comes from comparing a few focused ideas side by side.

• Spot potential value opportunities early by reviewing companies highlighted in the 49 high quality undervalued stocks that pair quality fundamentals with pricing that may warrant a closer look.
• Prioritise resilience by scanning stocks in the 85 resilient stocks with low risk scores that combine lower risk scores with characteristics some investors look for when aiming to protect capital.
• Seek out underfollowed prospects by checking the screener containing 20 high quality undiscovered gems that surface companies with solid fundamentals which fewer investors may be watching.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.